Q-omics provides the consensus-scored CCBE1 profile across patient tissues and cancer cell-line models. CCBE1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CCBE1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, CCBE1 RNA expression shows 19,017 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, KIRC, and LSCC as cancer lineages where CCBE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCBE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCBE1 survival associations across molecular data types. CCBE1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCBE1 RNA expression–survival associations across cancer types. High CCBE1 expression shows unfavorable associations in STAD, HNSC, MESO, UVM and BLCA, but favorable associations in DLBC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CCBE1 RNA expression.
This table summarizes CCBE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCBE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCBE1 shows lower tumor expression in KIRC, KIRP, COAD, THCA and LUAD and higher tumor expression in HNSC. The KIRC box plot shows higher CCBE1 RNA expression in normal versus tumor tissue (log2 FC = −2.025, t-test p < 0.001).
This table shows molecular features associated with CCBE1 in patient tissues and cancer cell lines. In patient samples, CCBE1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCBE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
